The Effects of PegIntron Plus Rebetol in Subjects With Chronic Hepatitis C Not Responding to Pegasys (Study P03833)
Status:
Terminated
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
This is an uncontrolled, non-randomized, open-label, multinational study designed to evaluate
the efficacy and safety of PegIntron plus Rebetol in subjects with chronic hepatitis C. The
study is designed to determine the proportion of chronic hepatitis C genotype 1 subjects who
did not respond to previous treatment with Pegasys 180µg QW plus ribavirin, that will achieve
sustained virological response (SVR) when treated with PegIntron plus Rebetol.